WO2021150187A1 - Capsule-in-capsule comprising dabigatran etexilate - Google Patents

Capsule-in-capsule comprising dabigatran etexilate Download PDF

Info

Publication number
WO2021150187A1
WO2021150187A1 PCT/TR2021/050027 TR2021050027W WO2021150187A1 WO 2021150187 A1 WO2021150187 A1 WO 2021150187A1 TR 2021050027 W TR2021050027 W TR 2021050027W WO 2021150187 A1 WO2021150187 A1 WO 2021150187A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
formulation
composition according
dabigatran etexilate
pharmaceutically acceptable
Prior art date
Application number
PCT/TR2021/050027
Other languages
French (fr)
Inventor
Busra YAVUZ
Yildiz Gulkok
Arzu PALANTOKEN
Salih Sermet BASARAN
Fatih Sunel
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2021150187A1 publication Critical patent/WO2021150187A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

  • the present invention relates to a capsule-in-capsule composition
  • a capsule-in-capsule composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof characterized in that one of the capsules is filled with a liquid formulation.
  • Dabigatran is a potent, reversible, univalent direct thrombin inhibitor. Dabigatran was first disclosed in WO98/37075, which claimed compounds with a thrombin-inhibiting effect and the effect of prolonging the thrombin time, under the name 1 -methyl-2-[N-[4-(N-n- hexyloxycarbonylamidino) phenyl] aminomethyl] benzimidazol-5-ylcarboxylic acid-N-(2- pyridyl)-N-(2 ethoxycarbonylethyl)amides.
  • Dabigatran etexilate a novel direct thrombin inhibitor, is a prodrug of dabigatran and is a non-peptide thrombin inhibitor.
  • the structural formula is:
  • Dabigatran is currently available as dabigatran etexilate mesylate, under the trade name Pradaxa from Boehringer Ingelheim is used for the reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
  • the solubility of dabigatran etexilate mesylate in water is 1.8 mg/mL and dependent on the pH value.
  • EP1658056B1 suggests a tablet formulation containing dabigatran etexilate and an organic acid with a solubility in water of > 1 g / 250 ml at 20°C.
  • EP2740471 B1 discloses a pharmaceutical composition contains the following main components: a core material comprising an inorganic acid layer, an active substance layer and an insulating layer between inorganic acid layer and active substance layer.
  • EP2588090A2 discloses a process for the preparation of an oral dosage comprising a spherical core coated with tartaric acid, a isolating layer on the coated tartaric acid layer and a layer comprising dabigatran etexilate on the isolating layer.
  • WO2015145462A1 discloses a pharmaceutical composition comprising a first component in the form of tablet comprising dabigatran and a second component in the form of capsule comprising organic acid.
  • the main object of the present invention is to provide a capsule-in-capsule composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof which one of the capsules is filled with a liquid formulation.
  • capsule-in-capsule comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof provides desired stability and effective dissolution profile.
  • Another object of the present invention is to provide an easy and cost-effective process for the preparation of the said pharmaceutical composition.
  • capsule-in-capsule means a form is comprising a first capsule and a second capsule which is located within the first capsule.
  • a capsule-in-capsule composition comprises ; a) First capsule has first formulation which comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation. b) Second capsule has second formulation which comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation.
  • a capsule-in-capsule form comprises a first capsule and a second capsule which is located within the first capsule, wherein the first capsule comprising a first formulation held between the first and second capsule and comprising a second formulation held in the second capsule, and wherein the first formulation or the second formulation comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation.
  • dabigatran etexilate in the form of the free base is used.
  • the first formulation comprises dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof
  • the second formulation comprises a liquid formulation.
  • the first formulation comprises a liquid formulation
  • the second formulation comprises dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.
  • the composition provides stability in a single dosage unit.
  • LFHC technology liquid filled hard capsule
  • LFHC technology liquid filled hard capsule
  • the stability of the composition is very proper especially when considering the features of dabigatran and this method eliminates both incompatibility and stability problems encountered in the prior art.
  • a liquid formulation comprises solubility enhancing agents.
  • Suitable solubility enhancing agent is selected from the group comprising polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), glycerin, propylene glycol, ethanol, gelucire, cremophor (EL, RH 40, RH 60), isostearyl diglyceryl succinate (Imvitor) (191 , 308, 742, 780 K, 928, 988), transesterified ethoxylated vegetable oil (labrafil), lauroglycol, polaxamer, polyethylene glycol sorbitan, sodium lauryl sulfate or mixtures thereof.
  • the solubility enhancing agent is polyethylene glycol (PEG).
  • the solubility enhancing agent is polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), sodium lauryl sulfate or mixtures thereof.
  • the first formulation or second formulation is comprising in the form of mini tablets or granules or pellets or powder or beads or liquid or mixtures thereof.
  • the first formulation is comprising in the form of mini tablets or granules or pellets or powder or beads or mixtures thereof.
  • pellets refers to small particles with approximately uniform shapes and sizes produced by an extrusion process.
  • a “small particle” refers to a particle of which diameter, length, height, and width is at most 10 mm (e.g., at most 2, 3, 4, 5, 6, 7, 8, or 9 mm).
  • mini tablet refers to small tablets with a diameter equal to or less than 4 mm that are typically filled into a capsule or further compressed into larger tablets. Thickness of this mini tablets equal to or less than 3 mm.
  • the mini tablets have round shape and smooth surface to ease coating process.
  • the first formulation or the second formulation further comprises at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, binders, anti caking agents, lubricants, glidants, coating agents, solvents or mixtures thereof.
  • the first formulation further comprises at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, binders, anti-caking agents, lubricants, glidants, coating agents, solvents or mixtures thereof.
  • Suitable fillers is selected from the group comprising microcrystalline cellulose, microcrystalline cellulose pellet, mannitol, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • the filler is microcrystalline cellulose or microcrystalline cellulose pellet or mixtures thereof.
  • the amount of fillers is between 5.0% and 50.0% by weight of the first formulation.
  • the amount of fillers is between 5.0% and 25.0%, between 10.0% and 50.0%, between 15.0% and 50.0%, between 10.0% and 40.0% by weight of the first formulation.
  • Suitable disintegrant is selected from the group comprising cross-linked carboxymethyl cellulose (croscarmellose sodium), cross-linked polyvinylpyrrolidone (crospovidone), povidone, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, polyacrylate potassium, sodium alginate, sodium starch glycolate, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • the disintegrant is cross-linked carboxymethyl cellulose (croscarmellose sodium).
  • the amount of disintegrant is between 1 .0% and 15.0%, between 5.0% and 15.0% by weight of the first formulation.
  • Suitable binder is selected from the group comprising hydroxypropyl methyl cellulose, glyceryl behenate, polycarbophil, polyvinyl acetate and its copolymers, cellulose acetate phthalate, hydroxypropyl starch, cetostearyl alcohol, acacia mucilage, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, sodium alginate, hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, ethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, carrageenan, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponite, bentonite, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is hydroxypropyl methyl cellulose.
  • the amount of binders is between 5.0% and 30.0% by weight of the first formulation.
  • the amount of binders is between 5.0% and 15.0%, between 10.0% and 30.0% by weight of the first formulation.
  • Suitable anti-caking agent is selected from the group comprising talc, calcium phosphate, tribasic, calcium silicate, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate or mixtures thereof.
  • anti-caking agent is talc.
  • the amount of anti-caking agent is between 2.0% and 30.0% by weight of the first formulation.
  • Suitable lubricants is selected from the group comprising magnesium stearate, calcium stearate, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, glyceryl palmito stearate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • the lubricant is magnesium stearate.
  • Suitable glidants is selected from the group comprising colloidal silicon dioxide, aluminium silicate, silica or mixtures thereof.
  • the glidant is colloidal silicon dioxide.
  • Suitable solvents is selected from the group comprising 2-propanol, water, ethyl alcohol or mixtures thereof.
  • the capsule-in-capsule comprises at least one coating agent which having water-soluble polymer.
  • Suitable water-soluble polymer is selected from hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), hydroxyethylcellulose and derivatives, ethylcellulose and ethyl hydroxyethylcellulose, carboxymethylcellulose (CMC), methyl cellulose (MC), polyvinyl alcohol (PVA), polyethylene oxide (PEO), polyethylene oxide-b-propylene oxide), polyoxyethylene (POE), polyethylenimine (PEI), poly(N-vinylpyrrolidone/vinyl acetate), polyvinylpyrollidone PVP K-90, poly(vinylamine) hydrochloride, poly(2-hydroxypropyl methacrylate), polyacrylamides (PAM), polymethacrylamide, poly(N-isopropylacrylamide) (PNIPAM), poly(2-oxazoline), poly(2-ethyl-2-oxazoline), poly (3-chloro-2-hydroxypropyl-2- methacryloxyeth
  • the water-soluble polymer is hydroxypropyl methylcellulose (HPMC) or hydroxypropyl cellulose (HPC) or mixtures thereof.
  • Dabigatran etexilate is able to maintain its stability against heat and light under hardened conditions, while moisture is degraded.
  • the second capsule can be coated with at least one coating comprising water-soluble polymer.
  • the weight of at least one coating is between 1.0% and 20.0% or between 5.0% and 20.0% in the composition. It is used in such a small proportion provides an advantage in terms of stability without causing any delay in resolution.
  • the capsule-in capsule composition is free of an organic acid and inorganic acid.
  • organic acid or inorganic acid refers to the following excipients which is selected from the group comprising citric acid, tartaric acid, gallic acid, orotic acid, p- coumaric acid, hippuric acid, ferulic acid, vanillic acid, fumaric acid, maleic acid, succinic acid, malic acid, glutamic acid, aspartic acid, oxalic acid, lactic acid, formic acid, acetic acid, propionic acid, caproic acid, benzoic acid, carbonic acid, adipic acid.
  • Example 1 First formulation is in the form mini tablet, second formulation comprising a liquid formulation
  • Example 2 First formulation is in the form mini tablet, second formulation comprising a liquid formulation A process for example 1 or 2;
  • first capsule For first capsule, a) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose and croscarmellose sodium, b) Granulating with water, c) Drying and sieving, d) Adding colloidal Silicon dioxide, then mixing, e) Adding magnesium stearate, then mixing, f) Pressing to form mini-tablet, g) Filling the mini-tablets into first capsule.
  • Example 3 First formulation is in the form pellet, second formulation comprising a liquid formulation q.s.: quantity sufficient
  • Example 4 First formulation is in the form pellet, second formulation comprising a liquid formulation q.s.: quantity sufficient
  • first capsule For first capsule, a) Dissolving at least one coating agent in 2-propanol-water and then mixing, b) Adding dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and then, adding talc and obtained a suspension c) Coating microcrystalline cellulose pellets with the suspension on step b), d) Filling the pellets into first capsule.
  • Example 5 First formulation is in the form granule, second formulation comprising a liquid formulation
  • Example 6 First formulation is in the form granule, second formulation comprising a liquid formulation
  • first capsule For first capsule, a) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium, b) Granulating the mixture with water, c) Drying and sieving, d) Adding magnesium stearate, then mixing, e) Filling the mixture into first capsule.
  • Example 7 First formulation comprising a liquid formulation, second formulation is in the form mini tablet
  • Example 8 First formulation comprising a liquid formulation, second formulation is in the form mini tablet
  • Second capsule c) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose and croscarmellose sodium, d) Granulating with water, e) Drying and sieving, f) Adding colloidal Silicon dioxide, then mixing, g) Adding magnesium stearate, then mixing, h) Pressing to form mini-tablet, i) Filling the mini-tablets into second capsule.
  • Example 9 First formulation comprising a liquid formulation, second formulation is in the form pellet
  • Example 10 First formulation comprising a liquid formulation, second formulation is in the form pellet
  • For the first capsule a) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, b) Filling the liquid mixture into the second capsule
  • For second capsule c) Dissolving at least one coating agent in 2-propanol-water and then mixing, d) Adding dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and then, adding talc and obtained a suspension
  • Example 11 First formulation comprising a liquid formulation, second formulation is in the form granule
  • Example 12 First formulation comprising a liquid formulation, second formulation is in the form granule
  • Second capsule c) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium, d) Granulating the mixture with water, e) Drying and sieving, f) Adding magnesium stearate, then mixing, g) Filling the mixture into second capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a capsule-in-capsule composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof characterized in that one of the capsules is filled with a liquid formulation.

Description

CAPSULE-IN-CAPSULE COMPRISING DABIGATRAN ETEXILATE
DESCRIPTION
Field of the Invention
The present invention relates to a capsule-in-capsule composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof characterized in that one of the capsules is filled with a liquid formulation.
Background of the Invention
Dabigatran is a potent, reversible, univalent direct thrombin inhibitor. Dabigatran was first disclosed in WO98/37075, which claimed compounds with a thrombin-inhibiting effect and the effect of prolonging the thrombin time, under the name 1 -methyl-2-[N-[4-(N-n- hexyloxycarbonylamidino) phenyl] aminomethyl] benzimidazol-5-ylcarboxylic acid-N-(2- pyridyl)-N-(2 ethoxycarbonylethyl)amides.
Dabigatran etexilate, a novel direct thrombin inhibitor, is a prodrug of dabigatran and is a non-peptide thrombin inhibitor. The structural formula is:
Figure imgf000002_0001
Formula 1 : Dabigatran etexilate
Dabigatran is currently available as dabigatran etexilate mesylate, under the trade name Pradaxa from Boehringer Ingelheim is used for the reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
The solubility of dabigatran etexilate mesylate in water is 1.8 mg/mL and dependent on the pH value. To increase the solubility of dabigatran etexilate, EP1658056B1 suggests a tablet formulation containing dabigatran etexilate and an organic acid with a solubility in water of > 1 g / 250 ml at 20°C.
Dabigatran etexilate is also less stable in acidic environment. To avoid stability problem, many solutions were offered in the prior art. EP2740471 B1 discloses a pharmaceutical composition contains the following main components: a core material comprising an inorganic acid layer, an active substance layer and an insulating layer between inorganic acid layer and active substance layer. EP2588090A2 discloses a process for the preparation of an oral dosage comprising a spherical core coated with tartaric acid, a isolating layer on the coated tartaric acid layer and a layer comprising dabigatran etexilate on the isolating layer. WO2015145462A1 discloses a pharmaceutical composition comprising a first component in the form of tablet comprising dabigatran and a second component in the form of capsule comprising organic acid.
There is still a need to prepare alternate compositions of dabigatran etexilate that are desired stability and improved dissolution profile. We have found an easy way to provide the desired stability at a composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof. Thus, it also provides improvement in dissolution profile.
Detailed Description of the Invention
The main object of the present invention is to provide a capsule-in-capsule composition comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof which one of the capsules is filled with a liquid formulation. Thereof, capsule-in-capsule comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof provides desired stability and effective dissolution profile.
Another object of the present invention is to provide an easy and cost-effective process for the preparation of the said pharmaceutical composition.
As used here in, ‘capsule-in-capsule’ means a form is comprising a first capsule and a second capsule which is located within the first capsule.
According to one embodiment of the present invention, a capsule-in-capsule composition comprises ; a) First capsule has first formulation which comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation. b) Second capsule has second formulation which comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation.
In one embodiment, a capsule-in-capsule form comprises a first capsule and a second capsule which is located within the first capsule, wherein the first capsule comprising a first formulation held between the first and second capsule and comprising a second formulation held in the second capsule, and wherein the first formulation or the second formulation comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation.
According to one embodiment of the present invention, dabigatran etexilate in the form of the free base is used.
According to one embodiment of the present invention, the first formulation comprises dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, the second formulation comprises a liquid formulation.
According to one embodiment of the present invention, the first formulation comprises a liquid formulation, the second formulation comprises dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.
According to one embodiment of the present invention, the composition provides stability in a single dosage unit. Especially, using LFHC technology (liquid filled hard capsule) in liquid formulation has surprisingly provided the stability of the composition. To prepare a capsule with LFFIC at capsule-in-capsule form is very proper especially when considering the features of dabigatran and this method eliminates both incompatibility and stability problems encountered in the prior art.
According to one embodiment of the present invention, a liquid formulation comprises solubility enhancing agents. Suitable solubility enhancing agent is selected from the group comprising polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), glycerin, propylene glycol, ethanol, gelucire, cremophor (EL, RH 40, RH 60), isostearyl diglyceryl succinate (Imvitor) (191 , 308, 742, 780 K, 928, 988), transesterified ethoxylated vegetable oil (labrafil), lauroglycol, polaxamer, polyethylene glycol sorbitan, sodium lauryl sulfate or mixtures thereof.
According to one embodiment of the present invention, the solubility enhancing agent is polyethylene glycol (PEG).
According to one embodiment of the present invention, the solubility enhancing agent is polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), sodium lauryl sulfate or mixtures thereof.
According to one embodiment of the present invention, the first formulation or second formulation is comprising in the form of mini tablets or granules or pellets or powder or beads or liquid or mixtures thereof.
According to one embodiment of the present invention, the first formulation is comprising in the form of mini tablets or granules or pellets or powder or beads or mixtures thereof.
The term “pellets” refers to small particles with approximately uniform shapes and sizes produced by an extrusion process. A “small particle” refers to a particle of which diameter, length, height, and width is at most 10 mm (e.g., at most 2, 3, 4, 5, 6, 7, 8, or 9 mm).
The term “mini tablet”, as used herein, refers to small tablets with a diameter equal to or less than 4 mm that are typically filled into a capsule or further compressed into larger tablets. Thickness of this mini tablets equal to or less than 3 mm. The mini tablets have round shape and smooth surface to ease coating process.
In one embodiment, the first formulation or the second formulation further comprises at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, binders, anti caking agents, lubricants, glidants, coating agents, solvents or mixtures thereof. Preferably, only the first formulation further comprises at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, binders, anti-caking agents, lubricants, glidants, coating agents, solvents or mixtures thereof. Suitable fillers is selected from the group comprising microcrystalline cellulose, microcrystalline cellulose pellet, mannitol, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
According to one embodiment of the present invention, the filler is microcrystalline cellulose or microcrystalline cellulose pellet or mixtures thereof.
According to one embodiment of the present invention, the amount of fillers is between 5.0% and 50.0% by weight of the first formulation.
According to one embodiment of the present invention, the amount of fillers is between 5.0% and 25.0%, between 10.0% and 50.0%, between 15.0% and 50.0%, between 10.0% and 40.0% by weight of the first formulation.
Suitable disintegrant is selected from the group comprising cross-linked carboxymethyl cellulose (croscarmellose sodium), cross-linked polyvinylpyrrolidone (crospovidone), povidone, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, polyacrylate potassium, sodium alginate, sodium starch glycolate, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
According to one embodiment of the present invention, the disintegrant is cross-linked carboxymethyl cellulose (croscarmellose sodium).
According to one embodiment of the present invention, the amount of disintegrant is between 1 .0% and 15.0%, between 5.0% and 15.0% by weight of the first formulation.
Suitable binder is selected from the group comprising hydroxypropyl methyl cellulose, glyceryl behenate, polycarbophil, polyvinyl acetate and its copolymers, cellulose acetate phthalate, hydroxypropyl starch, cetostearyl alcohol, acacia mucilage, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, sodium alginate, hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, ethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, carrageenan, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponite, bentonite, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
According to one embodiment of the present invention, the binder is hydroxypropyl methyl cellulose.
According to one embodiment of the present invention, the amount of binders is between 5.0% and 30.0% by weight of the first formulation.
According to one embodiment of the present invention, the amount of binders is between 5.0% and 15.0%, between 10.0% and 30.0% by weight of the first formulation.
Suitable anti-caking agent is selected from the group comprising talc, calcium phosphate, tribasic, calcium silicate, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate or mixtures thereof.
According to one embodiment of the present invention, anti-caking agent is talc.
According to one embodiment of the present invention, the amount of anti-caking agent is between 2.0% and 30.0% by weight of the first formulation.
Suitable lubricants is selected from the group comprising magnesium stearate, calcium stearate, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, glyceryl palmito stearate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
According to one embodiment of the present invention, the lubricant is magnesium stearate.
Suitable glidants is selected from the group comprising colloidal silicon dioxide, aluminium silicate, silica or mixtures thereof.
According to one embodiment of the present invention, the glidant is colloidal silicon dioxide.
Suitable solvents is selected from the group comprising 2-propanol, water, ethyl alcohol or mixtures thereof.
According to an embodiment of the present invention, the capsule-in-capsule comprises at least one coating agent which having water-soluble polymer.
Suitable water-soluble polymer is selected from hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), hydroxyethylcellulose and derivatives, ethylcellulose and ethyl hydroxyethylcellulose, carboxymethylcellulose (CMC), methyl cellulose (MC), polyvinyl alcohol (PVA), polyethylene oxide (PEO), polyethylene oxide-b-propylene oxide), polyoxyethylene (POE), polyethylenimine (PEI), poly(N-vinylpyrrolidone/vinyl acetate), polyvinylpyrollidone PVP K-90, poly(vinylamine) hydrochloride, poly(2-hydroxypropyl methacrylate), polyacrylamides (PAM), polymethacrylamide, poly(N-isopropylacrylamide) (PNIPAM), poly(2-oxazoline), poly(2-ethyl-2-oxazoline), poly (3-chloro-2-hydroxypropyl-2- methacryloxyethyldimethyl-ammonium chloride), poly(2-vinyl-1-methylpyridinium bromide), poly(2-vinylpyridine), polyamines, poly(2-vinylpyridine N-oxide), poly(N-vinylpyrrolidone/2- dimethylaminoethyl methacrylate) dimethyl sulfate quaternary, sodium alginate, starch or mixture thereof.
According to an embodiment of the present invention, the water-soluble polymer is hydroxypropyl methylcellulose (HPMC) or hydroxypropyl cellulose (HPC) or mixtures thereof.
Dabigatran etexilate is able to maintain its stability against heat and light under hardened conditions, while moisture is degraded. In order to protect the dabigatran etexylate in a capsule from the moisture of the other capsule, the second capsule can be coated with at least one coating comprising water-soluble polymer. The weight of at least one coating is between 1.0% and 20.0% or between 5.0% and 20.0% in the composition. It is used in such a small proportion provides an advantage in terms of stability without causing any delay in resolution.
According to one embodiment of the present invention, the capsule-in capsule composition is free of an organic acid and inorganic acid.
In this application, the term ‘organic acid or inorganic acid’ refers to the following excipients which is selected from the group comprising citric acid, tartaric acid, gallic acid, orotic acid, p- coumaric acid, hippuric acid, ferulic acid, vanillic acid, fumaric acid, maleic acid, succinic acid, malic acid, glutamic acid, aspartic acid, oxalic acid, lactic acid, formic acid, acetic acid, propionic acid, caproic acid, benzoic acid, carbonic acid, adipic acid.
The pharmaceutical combination of the present invention is prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion, spheronization, slugging, spray drying or solvent evaporation. Example 1 : First formulation is in the form mini tablet, second formulation comprising a liquid formulation
Figure imgf000009_0001
Example 2: First formulation is in the form mini tablet, second formulation comprising a liquid formulation
Figure imgf000010_0001
A process for example 1 or 2;
For first capsule, a) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose and croscarmellose sodium, b) Granulating with water, c) Drying and sieving, d) Adding colloidal Silicon dioxide, then mixing, e) Adding magnesium stearate, then mixing, f) Pressing to form mini-tablet, g) Filling the mini-tablets into first capsule.
For the second capsule, h) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, i) Filling the liquid mixture into the second capsule
Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.
Example 3: First formulation is in the form pellet, second formulation comprising a liquid formulation
Figure imgf000011_0001
q.s.: quantity sufficient Example 4: First formulation is in the form pellet, second formulation comprising a liquid formulation
Figure imgf000012_0001
q.s.: quantity sufficient
A process for example 3 or 4;
For first capsule, a) Dissolving at least one coating agent in 2-propanol-water and then mixing, b) Adding dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and then, adding talc and obtained a suspension c) Coating microcrystalline cellulose pellets with the suspension on step b), d) Filling the pellets into first capsule.
For the second capsule, e) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, f) Filling the liquid mixture into the second capsule
Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.
Example 5: First formulation is in the form granule, second formulation comprising a liquid formulation
Figure imgf000013_0001
Example 6: First formulation is in the form granule, second formulation comprising a liquid formulation
Figure imgf000014_0001
A process for example 5 or 6;
For first capsule, a) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium, b) Granulating the mixture with water, c) Drying and sieving, d) Adding magnesium stearate, then mixing, e) Filling the mixture into first capsule.
For the second capsule, f) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, g) Filling the liquid mixture into the second capsule
Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.
Example 7: First formulation comprising a liquid formulation, second formulation is in the form mini tablet
Figure imgf000015_0001
Example 8: First formulation comprising a liquid formulation, second formulation is in the form mini tablet
Figure imgf000016_0001
A process for example 7 or 8;
For the first capsule, a) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, b) Filling the liquid mixture into the second capsule
For second capsule, c) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose and croscarmellose sodium, d) Granulating with water, e) Drying and sieving, f) Adding colloidal Silicon dioxide, then mixing, g) Adding magnesium stearate, then mixing, h) Pressing to form mini-tablet, i) Filling the mini-tablets into second capsule.
Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.
Example 9: First formulation comprising a liquid formulation, second formulation is in the form pellet
Figure imgf000017_0001
Example 10: First formulation comprising a liquid formulation, second formulation is in the form pellet
Figure imgf000018_0001
A process for example 9 or 10; For the first capsule, a) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, b) Filling the liquid mixture into the second capsule For second capsule, c) Dissolving at least one coating agent in 2-propanol-water and then mixing, d) Adding dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and then, adding talc and obtained a suspension e) Coating microcrystalline cellulose pellets with the suspension on step b), f) Filling the pellets into second capsule.
Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.
Example 11 : First formulation comprising a liquid formulation, second formulation is in the form granule
Figure imgf000019_0001
Example 12: First formulation comprising a liquid formulation, second formulation is in the form granule
Figure imgf000020_0001
A process for example 11 or 12;
For the first capsule, a) Mixing PEG, polyvinylpyrrolidone and sodium lauryl sulfate, b) Filling the liquid mixture into the second capsule
For second capsule, c) Mixing dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium, d) Granulating the mixture with water, e) Drying and sieving, f) Adding magnesium stearate, then mixing, g) Filling the mixture into second capsule.
Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.

Claims

1 . A capsule-in-capsule composition comprising ; a. First capsule has first formulation which comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation. b. Second capsule has second formulation which comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or a liquid formulation.
2. The capsule-in-capsule composition according to claim 1 , wherein the second capsule comprising second formulation is located within the first capsule.
3. The capsule-in-capsule composition according to claim 1 , wherein dabigatran etexilate in the form of the free base is used.
4. The capsule-in-capsule composition according to claim 1 , wherein the first formulation comprises dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof, the second formulation comprises a liquid formulation.
5. The capsule-in-capsule composition according to claim 1 , wherein the first formulation comprises a liquid formulation, the second formulation comprises dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.
6. The capsule-in-capsule composition according to claim 4 or 5, wherein a liquid formulation comprising solubility enhancing agents which is selected from the group comprising polyethylene glycol, polyvinylpyrrolidone, glycerin, propylene glycol, ethanol, gelucire, cremophor, isostearyl diglyceryl succinate, transesterified ethoxylated vegetable oil, lauroglycol, polaxamer, polyethylene glycol sorbitan, sodium lauryl sulfate or mixtures thereof.
7. The capsule-in-capsule composition according to claim 6, wherein the solubility enhancing agent is polyethylene glycol.
8. The capsule-in-capsule composition according to claim 6, wherein the solubility enhancing agent is polyethylene glycol, polyvinylpyrrolidone, sodium lauryl sulfate or mixtures thereof.
9. The capsule-in-capsule composition according to any preceding claims, wherein the first formulation is comprising in the form of mini tablets or granules or pellets or powder or beads or mixtures thereof.
10. The capsule-in-capsule composition according to claim 4, wherein the first formulation further comprising at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, binders, anti-caking agents, lubricants, glidants, coating agents, solvents or mixtures thereof.
11. The capsule-in-capsule composition according to any preceding claims, wherein the capsule-in capsule composition is free of an organic acid and inorganic acid.
PCT/TR2021/050027 2020-01-20 2021-01-15 Capsule-in-capsule comprising dabigatran etexilate WO2021150187A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/00791A TR202000791A1 (en) 2020-01-20 2020-01-20 Capsule-in-capsule comprising dabigatran etexilate
TR2020/00791 2020-01-20

Publications (1)

Publication Number Publication Date
WO2021150187A1 true WO2021150187A1 (en) 2021-07-29

Family

ID=76993383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050027 WO2021150187A1 (en) 2020-01-20 2021-01-15 Capsule-in-capsule comprising dabigatran etexilate

Country Status (2)

Country Link
TR (1) TR202000791A1 (en)
WO (1) WO2021150187A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007710A2 (en) * 2000-07-20 2002-01-31 Mw Encap Limited Delivery device
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor
WO2019004980A2 (en) * 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007710A2 (en) * 2000-07-20 2002-01-31 Mw Encap Limited Delivery device
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor
WO2019004980A2 (en) * 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate

Also Published As

Publication number Publication date
TR202000791A1 (en) 2021-07-26

Similar Documents

Publication Publication Date Title
US20200163882A1 (en) Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
WO2016062860A1 (en) Amorphous vortioxetine hydrobromide
EP2722034B1 (en) Oral pharmaceutical formulations comprising dabigatran
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
WO2019004980A2 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
US20120035177A1 (en) Tablet formulation for p38 inhibitor and method
WO2021150187A1 (en) Capsule-in-capsule comprising dabigatran etexilate
WO2013008253A2 (en) Imatinib formulations
EP3787624A2 (en) Capsule-in-capsule compositions of dabigatran etexilate
AU2018293361B2 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
EP3731822A1 (en) Oral pharmaceutical compositions of dabigatran
WO2020209813A1 (en) A capsule formulation of dabigatran etexilate
EP3731824B1 (en) Pharmaceutical tablet compositions of dabigatran
WO2024144679A2 (en) A tablet formulation comprising selexi̇pag
WO2024144726A1 (en) Formulations comprising selexipag
WO2020048449A1 (en) Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof
EP4393476A1 (en) A tablet formulation comprising selexipag
EP4393475A1 (en) Formulations comprising selexipag
EP4393474A1 (en) A formulation comprising selexipag
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
EP3731823A1 (en) A pharmaceutical formulation for oral administration comprising dabigatran etexilate
EP4140478A1 (en) A solid pharmaceutical composition comprising sacubitril and valsartan
WO2023195954A1 (en) A film coated tablet comprising a solid dispersion of selexi̇pag

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21743780

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21743780

Country of ref document: EP

Kind code of ref document: A1